Lablabo creates pack for HRT treatment

Published: 24-Jan-2011
Drug Delivery Pharmaceutical

Uses an airless metering dispenser with EasyFoil aluminium pouch

Lablabo of France has developed a high-performance airless pack for Azur Pharma’s Elestrin hormonal replacement therapy, which has been launched in the US following approval by the US Food and Drug Administration.

Lablabo’s pack consists of a Sillage airless metering dispenser with an EasyFoil aluminium pouch.

Made of an aluminium and polyethylen multilayer foil, this new pouch is said to ensure maximum protection of the product inside against oxygen and UV rays. Its cylindrical shape guarantees high restitution rates (up to 98% of the product delivered) and easy filling with basic equipment, the firm says.

The metering pump delivers a constant and precise dose of 0.92ml.

The Elestrin sales pack used by the Irish pharmaceutical firm includes two 38ml Sillage airless metering dispensers for a two-month treatment.

Lablabo, based in Annemasse, says it has Drug Master Files (DMFs) registered with the FDA for all of it products and received ISO 15378 certification last December.

See more

You may also like

Manufacturing

Rentschler Biopharma expands services in Japan and South Korea ahead of BioProcess International Asia

Read more
Rentschler Biopharma will showcase its Rentschler Expression Platform and Development Services at BioProcess International Asia in Kyoto, underscoring its commitment to supporting biopharma partners across Japan and South Korea

Trending Articles

  1. Sharp appoints Samantha Wilson Jones as General Counsel Sharp Services has appointed Samantha Wilson Jones as General Counsel and Corporate Secretary of Sharp
  2. Nanologica secures first insulin purification order in China The SEK 2m deal will see the company’s silica-based NLAB Saga evaluated at production scale by a Chinese insulin manufacturer
  3. Kindeva to showcase complex drug delivery expertise at CPHI 2025 Global CDMO highlights sterile injectable, pulmonary, nasal and dermal capabilities
  4. Designing and developing bioconjugates for clinical success Abzena shares new insights and technologies to accelerate safe and effective ADC development
  5. Gerresheimer Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Manufacturing

Rentschler Biopharma expands services in Japan and South Korea ahead of BioProcess International Asia

Rentschler Biopharma will showcase its Rentschler Expression Platform and Development Services at BioProcess International Asia in Kyoto, underscoring its commitment to supporting biopharma partners across Japan and South Korea
Finance

Nanologica secures first insulin purification order in China

The SEK 2m deal will see the company’s silica-based NLAB Saga evaluated at production scale by a Chinese insulin manufacturer
Manufacturing

Designing and developing bioconjugates for clinical success

Abzena shares new insights and technologies to accelerate safe and effective ADC development
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)

With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
Pharmaceutical

AIRPLAN S.A. showcases its dual strength in engineering and technology at CPHI 2025

AIRPLAN S.A. will once again participate in CPHI 2025, the world’s premier pharmaceutical event, taking place from October 28 to 30 in Frankfurt (Hall 9.0, booth B29)
Pharmaceutical

NEXTEN: Tomorrow's Tableting Innovations

A world première of the new IMA Active tablet presses
Pharmaceutical

Global vaccine patents up 7% in a year despite US government's stance

Vaccine patent applications show sustained momentum after the COVID pandemic, with RNA vaccines now dominating the filings
Subscribe now